Investigating the use of broad genomic profiling in advanced lung cancer treatment
Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care
This study is looking at how using broad genomic profiling can help doctors make better treatment choices for patients with advanced non-small cell lung cancer, so they can get the most effective care based on their individual genetic makeup.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10932365 on NIH RePORTER |
What this research studies
This research focuses on how broad genomic profiling (BGP) can improve treatment decisions for patients with advanced non-small cell lung cancer. By analyzing real-world data, the study aims to understand how BGP is utilized in clinical practice, its impact on treatment outcomes, and the costs associated with its use. The research will also explore the value of additional evidence to guide the adoption of BGP in cancer care, ensuring that patients receive the most effective treatments based on their unique genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced non-small cell lung cancer who may benefit from genomic profiling to guide their treatment.
Not a fit: Patients with early-stage lung cancer or those whose cancer is not advanced may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with advanced lung cancer.
How similar studies have performed: Previous research has shown promising results in using genomic profiling to tailor cancer treatments, indicating that this approach has potential for significant impact.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Gross, Cary P. — Yale University
- Study coordinator: Gross, Cary P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.